HIV

ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial
ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial
Pharmaceutical Business Review
ViiV Healthcare
HIV
clinical trials
fostemsavir
Flag link:
Long-lasting HIV injection is a step closer after second GSK study
Long-lasting HIV injection is a step closer after second GSK study
Reuters
vaccines
GSK
HIV
cabotegravir
rilpivirine
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
CP Wire
Janssen
JNJ
Symtuza
HIV
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen
JNJ
Symtuza
HIV
Flag link:
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Fierce Pharma
Gilead Sciences
HIV
Flag link:
Inovio touts intradermal delivery of HIV vaccine
Inovio touts intradermal delivery of HIV vaccine
Drug Delivery Business News
Invovio
HIV
vaccines
Pennvax-GP
Flag link:
US filing for ViiV’s two-drug, single pill HIV treatment
US filing for ViiV’s two-drug, single pill HIV treatment
Pharma Times
ViiV
FDA
HIV
dolutegravir/lamivudine
Flag link:
Gilead, Aelix ally to trial HIV-suppressing combination
Gilead, Aelix ally to trial HIV-suppressing combination
Fierce Biotech
Gilead Sciences
Aelix Therapeutics
vaccines
antiretrovirals
HIV
Flag link:
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV-1
HIV
Flag link:
Why Payers Sometimes Restrict Access To Single Tablet Regimens For HIV Patients
Why Payers Sometimes Restrict Access To Single Tablet Regimens For HIV Patients
Forbes
HIV
antiretrovirals
payers
Flag link:
T-cell therapy for eradicating HIV reservoirs proves safe in small study
T-cell therapy for eradicating HIV reservoirs proves safe in small study
Fierce Biotech
HIV
immunotherapy
Flag link:
What's Next for Gilead Sciences After Its Latest Clinical Success
What's Next for Gilead Sciences After Its Latest Clinical Success
Motley Fool
Gilead Sciences
John Milligan
HIV
NASH
filgotinib
Flag link:
Needed vaccines against HIV, malaria and tuberculosis unlikely to launch at current funding levels: study
Needed vaccines against HIV, malaria and tuberculosis unlikely to launch at current funding levels: study
Fierce Pharma
drug development
vaccines
HIV
tuberculosis
malaria
Flag link:
FDA approves two new HIV drugs from Merck
FDA approves two new HIV drugs from Merck
Reuters
Merck
HIV
FDA
Delstrigo
Pifeltro
Flag link:
Should Gilead Be Worried About This New Monthly HIV Medication?
Should Gilead Be Worried About This New Monthly HIV Medication?
Motley Fool
Gilead Sciences
HIV
JNJ
ViiV
cabotegravir
rilpivirine
Edurant
Flag link:
Long-acting injection boosts hopes for GSK's HIV business
Long-acting injection boosts hopes for GSK's HIV business
Yahoo/Reuters
GSK
HIV
AIDS
cabotegravir
rilpivirine
ViiV
Flag link:
AIDS health group brings Gilead patent skirmish to Supreme Court
AIDS health group brings Gilead patent skirmish to Supreme Court
Fierce Pharma
Gilead Sciences
AIDS
HIV
TAF
Supreme Court
Flag link:
Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It
Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It
Forbes
Gilead Sciences
HIV
Truvada
drug ads
Flag link:
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Bloomberg
Express Scripts
PBMs
Gilead Sciences
HIV
Atripla
AbbVie
Mavyret
hepatitis C
Flag link:
China Approves Gilead's Genvoya for HIV-1 Infection
China Approves Gilead's Genvoya for HIV-1 Infection
CP Wire
Gilead Sciences
China
Genvoya
HIV
Flag link:

Pages